Value20202021202220232024TTMSelling/general/admin expenses67.58 M76.18 M70.7 M69.65 M71.99 M54.9 MResearch & development158 M142.51 M174.96 M177.65 M199.25 M111.16 MOperating income134.84 M193.15 M225.95 M169.18 M251.15 M198.85 MNon-Operating Income, Total18.86 M644 K5.52 M15.96 M14.06 M3.53 MInterest expense, net of interest capitalized————2.13 M8.76 MNon-Operating Income, excl. Interest Expenses2.6 M-1.05 M4.22 M14.36 M11.93 M-7.41 MUnusual income/expense16.26 M1.7 M1.29 M1.6 M3 0002.17 MPretax income153.7 M193.79 M231.47 M185.14 M263.08 M193.62 MEquity in earnings——————Taxes-33.8 M-72.8 M000—Non-controlling/minority interest——————After tax other income/expense104 K1.66 M724 K1.6 M415 K390 KNet income before discontinued operations115.98 M192.5 M220.43 M153.22 M237.09 M199.84 MDiscontinued operations——————Net income115.98 M192.5 M220.43 M153.22 M237.09 M199.84 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders115.98 M-191.5 M-220.43 M153.22 M237.09 M199.84 MBasic earnings per share (Basic EPS)—-2.85-3.21-2.02-2.88-2.38Diluted earnings per share (Diluted EPS)—-2.83-3.21-2.02-2.88-2.38Average basic shares outstanding—67.62 M68.66 M75.97 M82.34 M339.9 MDiluted shares outstanding—67.62 M68.66 M75.97 M82.34 M339.9 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)4 M5.1 M6.3 M6.1 M5.86 M5.84 M
Editas Medicine Inc
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.